Verve Therapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19
	10-K	8-K	10-K	8-K	10-K	10-K
Revenues	1.9	130.1	0.0	68.2	0.0	0.0
Revenue growth		90.7%
Cost of goods sold	0.0	167.6	0.0	87.1	0.0	0.0
Gross profit	1.9	-37.5	0.0	-18.9	0.0	0.0
Gross margin	100.0%	-28.9%		-27.7%
Selling, general and administrative [+]	37.5	37.5	18.9	18.9	5.3	2.5
General and administrative	37.5	37.5	18.9	18.9	5.3	2.5
Research and development	130.1		68.2		35.4	11.1
Other operating expenses		90.6		49.3
EBITDA [+]	-162.9		-85.5		-39.3	-13.5
EBITDA growth	90.4%	90.3%	117.6%		190.3%
EBITDA margin	-8391.7%	-127.4%		-127.7%
Depreciation and amortization	2.8		1.5		1.3	0.1
EBIT [+]	-165.7	-165.7	-87.1	-87.1	-40.6	-13.6
EBIT growth	90.3%	90.3%	114.3%		197.8%
EBIT margin	-8536.2%	-127.4%		-127.7%
Other income (expense), net [+]	8.4	8.4	-33.2	-33.2	-5.1	-5.7
Other	6.9	8.4	0.1	-33.2	0.2	0.3
Pre-tax income	-157.3	-157.3	-120.3	-120.3	-45.7	-19.3
Income taxes	0.1	0.1	0.0	0.0	0.0	0.0
Tax rate			0.0%	0.0%	0.0%	0.0%
Net income	-157.4	-157.4	-120.3	-120.3	-45.7	-19.3
Net margin	-8108.6%	-121.0%		-176.4%

Basic EPS [+]	($2.91)	($2.91)	($4.48)	($4.48)	($20.31)	($15.11)
Growth	-34.9%	-35.0%	-78.0%		34.4%
Diluted EPS [+]	($2.91)	($2.91)	($4.48)	($4.48)	($20.31)	($15.11)
Growth	-34.9%	-35.0%	-78.0%		34.4%

Shares outstanding (basic) [+]	54.0	54.1	26.9	26.9	2.3	1.3
Growth	101.0%	101.4%	1094.3%		76.2%
Shares outstanding (diluted) [+]	54.0	54.1	26.9	26.9	2.3	1.3
Growth	101.0%	101.4%	1094.3%		76.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.